2019
DOI: 10.1007/s00520-018-4632-0
|View full text |Cite
|
Sign up to set email alerts
|

Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
35
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 46 publications
(38 citation statements)
references
References 23 publications
3
35
0
Order By: Relevance
“…The prevalence of symptoms at baseline differed according to the site of the primary tumor, as also reported elsewhere [24,25]. The association between specific tumor sites and cancer symptoms is clear, even at advanced stages of the disease when widespread metastasis can dilute this specificity.…”
Section: Discussionsupporting
confidence: 68%
“…The prevalence of symptoms at baseline differed according to the site of the primary tumor, as also reported elsewhere [24,25]. The association between specific tumor sites and cancer symptoms is clear, even at advanced stages of the disease when widespread metastasis can dilute this specificity.…”
Section: Discussionsupporting
confidence: 68%
“…The prevalence of symptoms at baseline differed according to the site of the primary tumor, as also reported elsewhere [22,23]. The association between speci c tumor sites and cancer symptoms is clear, even at advanced stages of the disease when widespread metastasis can dilute this speci city.…”
Section: Discussionsupporting
confidence: 66%
“…This scale does not evaluate coughing, a common symptom in lung cancer; as a standard of care and in clinical trials, the MDASI-LC test, which includes coughing, must be used to a complete evaluation of the patient's symptoms. 60 Widely used PRObased symptom assessment tools are needed to facilitate a comparison of results with those of other published studies. 61 Only one study 62 reported the use of a new electronic PRO: the NSCLC-SAQ, after Food and Drug Administration (FDA) qualification, will be publicly available to capture patient-reported NSCLC-related symptoms via electronic data entry platforms.…”
Section: Resultsmentioning
confidence: 99%
“…It must be emphasized that there is much evidence in the literature about the benefits of collecting and using PROs in lung cancer populations, for treatment monitoring, 35,[38][39][40][44][45][46][47][48]51,55,[57][58][59][65][66][67] detection of symptoms, 36,37,41,50,53,54,60,65 the role of patient or pathology characteristics on QoL, 40,42,56,68 to improve patientclinician communication and patient satisfaction. 43,61,62 Only one study about the effect of disease progression on QoL was identified 49 assessing the use of PROs related to efficacy outcomes (PFS, OS).…”
Section: Discussionmentioning
confidence: 99%